A new treatment for neurogenic inflammation caused by EV71 with CR2-targeted complement inhibitor

详细信息    查看全文

• 作者：Shaofu Qiu (1)
  Nan Liu (1)
  Leili Jia (1)
  Guang Yang (1)
  Wenli Su (1)
  Jing Li (1)
  Lixue Song (2)
  Chaojie Yang (1)
  Jian Wang (1)
  Chuanfu Zhang (1)
  Zhongqiang Wang (1)
  Fei Qiao (3)
  Stephen Tomlinson (3)
  Carl Atkinson (3)
  Yansong Sun (1)
  Liuyu Huang (1)
  Hongbin Song (1)
  Yong Wang (1)
  Zhenjun Li (4)
  
• 刊名：Virology Journal
• 出版年：2012
• 出版时间：December 2012
• 年：2012
• 卷：9
• 期：1
• 全文大小：149KB
• 参考文献：1. Wang SM, Liu CC: Enterovirus 71: epidemiology, pathogenesis and management. / Expert Rev Anti Infect Ther 2009, 7:735鈥?42. CrossRef
  2. Chen CS, Yao YC, Lin SC, Lee YP, Wang YF, Wang JR, Liu CC, Lei HY, Yu CK: Retrograde axonal transport: a major transmission route of enterovirus 71 in mice. / J Virol 2007, 81:8996鈥?003. CrossRef
  3. Weng KF, Chen LL, Huang PN, Shih SR: Neural pathogenesis of enterovirus 71 infection. / Microbes Infect 2010, 12:505鈥?10. CrossRef
  4. Lee MS, Chang LY: Development of enterovirus 71 vaccines. / Expert Rev Vaccines 2010, 9:149鈥?56. CrossRef
  5. Vallet S, Legrand Quillien MC, Dailland T, Podeur G, Gouriou S, Schuffenecker I, Payan C, Marcorelles P: Fatal case of enterovirus 71 infection, France, 2007. / Emerg Infect Dis 2009, 15:1837鈥?840. CrossRef
  6. Yu H, Chen W, Chang H, Tang R, Zhao J, Gan L, Liu B, Chen J, Wang M: Genetic analysis of the VP1 region of enterovirus 71 reveals the emergence of genotype A in central China in 2008. / Virus Genes 2010, 41:1鈥?. CrossRef
  7. Han JF, Cao RY, Jiang T, Yu M, Liu W, Tian X, Qin ED, Cao WC, Qin CF: Echovirus 30 in EV71-associated hand, foot and mouth disease outbreak, Guangxi, China. / J Clin Virol 2011, 50:348鈥?49. CrossRef
  8. Bible JM, Pantelidis P, Chan PK, Tong CY: Genetic evolution of enterovirus 71: epidemiological and pathological implications. / Rev Med Virol 2007, 17:371鈥?79. CrossRef
  9. McMinn PC: An overview of the evolution of enterovirus 71 and its clinical and public health significance. / FEMS Microbiol Rev 2002, 26:91鈥?07. CrossRef
  10. Jia CS, Liu JN, Li WB, Ma CM, Lin SZ, Hao Y, Gao XZ, Liu XL, Xu YF, Zhang LF, Qin C: The cross-reactivity of the enterovirus 71 to human brain tissue and identification of the cross-reactivity related fragments. / Virol J 2010, 7:47. CrossRef
  11. Wang SM, Lei HY, Huang KJ, Wu JM, Wang JR, Yu CK, Su IJ, Liu CC: Pathogenesis of enterovirus 71 brainstem encephalitis in pediatric patients: roles of cytokines and cellular immune activation in patients with pulmonary edema. / J Infect Dis 2003, 188:564鈥?70. CrossRef
  12. Lee TC, Guo HR, Su HJ, Yang YC, Chang HL, Chen KT: Diseases caused by enterovirus 71 infection. / Pediatr Infect Dis J 2009, 28:904鈥?10. CrossRef
  13. Lin TY, Chang LY, Huang YC, Hsu KH, Chiu CH, Yang KD: Different proinflammatory reactions in fatal and non-fatal enterovirus 71 infections: implications for early recognition and therapy. / Acta Paediatr 2002, 91:632鈥?35. CrossRef
  14. Lin TY, Hsia SH, Huang YC, Wu CT, Chang LY: Proinflammatory cytokine reactions in enterovirus 71 infections of the central nervous system. / Clin Infect Dis 2003, 36:269鈥?74. CrossRef
  15. Wang SM, Lei HY, Su LY, Wu JM, Yu CK, Wang JR, Liu CC: Cerebrospinal fluid cytokines in enterovirus 71 brain stem encephalitis and echovirus meningitis infections of varying severity. / Clin Microbiol Infect 2007, 13:677鈥?82. CrossRef
  16. Wang SM, Lei HY, Yu CK, Wang JR, Su IJ, Liu CC: Acute chemokine response in the blood and cerebrospinal fluid of children with enterovirus 71-associated brainstem encephalitis. / J Infect Dis 2008, 198:1002鈥?006. CrossRef
  17. Ricklin D, Hajishengallis G, Yang K, Lambris JD: Complement: a key system for immune surveillance and homeostasis. / Nat Immunol 2010, 11:785鈥?97. CrossRef
  18. Zhang C, Xu Y, Jia L, Yang Y, Wang Y, Sun Y, Huang L, Qiao F, Tomlinson S, Liu X, / et al.: A new therapeutic strategy for lung tissue injury induced by influenza with CR2 targeting complement inhibitor. / Virol J 2010, 7:30. CrossRef
  19. Sjoberg AP, Trouw LA, Blom AM: Complement activation and inhibition: a delicate balance. / Trends Immunol 2009, 30:83鈥?0. CrossRef
  20. Kopf M, Abel B, Gallimore A, Carroll M, Bachmann MF: Complement component C3 promotes T-cell priming and lung migration to control acute influenza virus infection. / Nat Med 2002, 8:373鈥?78. CrossRef
  21. Anderson DR, Carthy CM, Wilson JE, Yang D, Devine DV, McManus BM: Complement component 3 interactions with coxsackievirus B3 capsid proteins: innate immunity and the rapid formation of splenic antiviral germinal centers. / J Virol 1997, 71:8841鈥?845.
  22. Shih SR, Stollar V, Lin JY, Chang SC, Chen GW, Li ML: Identification of genes involved in the host response to enterovirus 71 infection. / J Neurovirol 2004, 10:293鈥?04. CrossRef
  23. Walport MJ: Complement. First of two parts. / N Engl J Med 2001, 344:1058鈥?066. CrossRef
  24. Song H, He C, Knaak C, Guthridge JM, Holers VM, Tomlinson S: Complement receptor 2-mediated targeting of complement inhibitors to sites of complement activation. / J Clin Invest 2003, 111:1875鈥?885.
  25. Walport MJ: Complement. Second of two parts. / N Engl J Med 2001, 344:1140鈥?144. CrossRef
  26. Atkinson C, Song H, Lu B, Qiao F, Burns TA, Holers VM, Tsokos GC, Tomlinson S: Targeted complement inhibition by C3d recognition ameliorates tissue injury without apparent increase in susceptibility to infection. / J Clin Invest 2005, 115:2444鈥?453. CrossRef
  27. Qiao F, Atkinson C, Song H, Pannu R, Singh I, Tomlinson S: Complement plays an important role in spinal cord injury and represents a therapeutic target for improving recovery following trauma. / Am J Pathol 2006, 169:1039鈥?047. CrossRef
  28. Atkinson C, Zhu H, Qiao F, Varela JC, Yu J, Song H, Kindy MS, Tomlinson S: Complement-dependent P-selectin expression and injury following ischemic stroke. / J Immunol 2006, 177:7266鈥?274.
  29. Huang Y, Qiao F, Atkinson C, Holers VM, Tomlinson S: A novel targeted inhibitor of the alternative pathway of complement and its therapeutic application in ischemia/reperfusion injury. / J Immunol 2008, 181:8068鈥?076.
  
• 作者单位：Shaofu Qiu (1)
  Nan Liu (1)
  Leili Jia (1)
  Guang Yang (1)
  Wenli Su (1)
  Jing Li (1)
  Lixue Song (2)
  Chaojie Yang (1)
  Jian Wang (1)
  Chuanfu Zhang (1)
  Zhongqiang Wang (1)
  Fei Qiao (3)
  Stephen Tomlinson (3)
  Carl Atkinson (3)
  Yansong Sun (1)
  Liuyu Huang (1)
  Hongbin Song (1)
  Yong Wang (1)
  Zhenjun Li (4)
  
  1. Institute of Disease Control and Prevention, Academy of Military Medical Sciences, Beijing, 100071, China
  2. Department of Pharmacology, General Hospital of Beijing Military Region, Beijing, 100700, China
  3. Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, South Carolina, 29425, USA
  4. State Key Laboratory for Infectious Disease Prevention and Control, National Institute for Communicable Diseases Prevention and Control, Chinese Center for Disease Control and Prevention, Beijing, 102206, China
  
• ISSN：1743-422X

文摘

Background Enterovirus 71 (EV71), one of the most important neurotropic EVs, has caused death and long-term neurological sequelae in hundreds of thousands of young children in the Asia-Pacific region in the past decade. The neurological diseases are attributed to infection by EV71 inducing an extensive peripheral and central nervous system (CNS) inflammatory response with abnormal cytokine production and lymphocyte depletion induced by EV71 infection. In the absence of specific antiviral agents or vaccines, an effective immunosuppressive strategy would be valuable to alleviate the severity of the local inflammation induced by EV71 infection. Presentation of the hypothesis The complement system plays a pivotal role in the inflammatory response. Inappropriate or excessive activation of the complement system results in a severe inflammatory reaction or numerous pathological injuries. Previous studies have revealed that EV71 infection can induce complement activation and an inflammatory response of the CNS. CR2-targeted complement inhibition has been proved to be a potential therapeutic strategy for many diseases, such as influenza virus-induced lung tissue injury, postischemic cerebral injury and spinal cord injury. In this paper, a mouse model is proposed to test whether a recombinant fusion protein consisting of CR2 and a region of Crry (CR2-Crry) is able to specifically inhibit the local complement activation induced by EV71 infection, and to observe whether this treatment strategy can alleviate or even cure the neurogenic inflammation. Testing the hypothesis CR2-Crry is expressed in CHO cells, and its biological activity is determined by complement inhibition assays. 7-day-old ICR mice are inoculated intracranially with EV71 to duplicate the neurological symptoms. The mice are then divided into two groups, in one of which the mice are treated with CR2-Crry targeted complement inhibitor, and in the other with phosphate-buffered saline. A group of mice deficient in complement C3, the breakdown products of which bind to CR2, are also infected with EV71 virus. The potential bioavailability and efficacy of the targeted complement inhibitor are evaluated by histology, immunofluorescence staining and radiolabeling. Implications of the hypothesis CR2-Crry-mediated targeting complement inhibition will alleviate the local inflammation and provide an effective treatment for the severe neurological diseases associated with EV71 infection.